Observational studyJNMA; journal of the Nepal Medical Association2025
Status of Antibiotic Susceptibility of Polymyxin B And Colistin in the Treatment of Carbapenem Resistant Gram Negative Bacterial Infections: An Observational Study.
Observational study in JNMA; journal of the Nepal Medical Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The emergence and rapid spread of multidrug-resistant gram-negative bacteria is a global concern. Polymyxin B and Colistin have gained significance due to the scarcity of new antibiotics and the high morbidity and mortality associated with carbapenem-resistant gram-negative bacteria. This study aims to assess the antibiotic susceptibility of Colistin and Polymyxin B against carbapenem-resistant gram-negative bacteria. Methods: This was a descriptive cross-sectional study conducted in a tertiary center of Nepal, from June to August 2025. Specimen resistant to any of the carbapenem drugs at the Clinical Laboratory was evaluated. The incidence of susceptibility or resistance of the Polymyxin and Colistin in the carbapenem-resistant gram-negative bacteria was recorded and assessed. Results: A total of 1,412 Gram-negative bacterial samples were analyzed within the predetermined study period. Among these samples, the prevalence of 395 (27.97%) was from carbapenem-resistant Gram-negative bacteria. There were 185 (46.84%) carbapenem-resistant Conclusions: Polymyxin B and Colistin continue to be vital last-line treatments for carbapenem-resistant gram-negative bacteria. This study found a susceptibility rate of 100% to colistin and polymyxin B among carbapenem-resistant gramnegative bacteria. To maintain the efficacy and reliability of these antibiotics, it is essential to use them judiciously, conduct routine susceptibility testing, and implement ongoing surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.